|
End-of-day quote
Egyptian Exchange
2026-11-10
|
5-day change | 1st Jan Change | ||
| 1.420 EGP | +5.19% |
|
+10.08% | +24.56% |
Business description: Macro Group Pharmaceuticals (Macro Capital) S.A.E

At the end of 2021, Macro Group Pharmaceutical S.A.E. (Macro Capital) had one production site in Egypt.
Sales by Activity: Macro Group Pharmaceuticals (Macro Capital) S.A.E
| Fiscal Period: December | 2021 (EGP) | 2022 (EGP) | 2023 (EGP) | 2024 (EGP) | 2025 (EGP) |
|---|---|---|---|---|---|
Manufacture and Sale of Pharmaceuticals | 594M | 730M | 526M | 520M | 895M |
Geographical breakdown of sales: Macro Group Pharmaceuticals (Macro Capital) S.A.E
| Fiscal Period: December | 2021 (EGP) | 2022 (EGP) | 2023 (EGP) | 2024 (EGP) | 2025 (EGP) |
|---|---|---|---|---|---|
Egypt | - | 699M | 511M | 485M | 864M |
Export | - | 30.46M | 15.02M | 34.67M | 30.8M |
Executive Committee: Macro Group Pharmaceuticals (Macro Capital) S.A.E
| Manager | Title | Age | Since |
|---|---|---|---|
Khaled Kamel
CEO | Chief Executive Officer | - | - |
Zeina Shahin
IRC | Investor Relations Contact | - | - |
Tamer Raouf
SAM | Sales & Marketing | - | 2021-12-31 |
Sherine Mostafa
HRO | Human Resources Officer | - | 2022-10-31 |
Composition of the Board of Directors: Macro Group Pharmaceuticals (Macro Capital) S.A.E
| Director | Title | Age | Since |
|---|---|---|---|
Ahmed El-Nayeb
CHM | Chairman | - | 2001-12-31 |
Tamir Saeed
BRD | Director/Board Member | - | 2020-12-31 |
Norbert Lurz
BRD | Director/Board Member | - | 2020-12-31 |
Ahmed Badreldin
BRD | Director/Board Member | 54 | 2020-12-31 |
| Director/Board Member | 38 | 2020-12-31 | |
Sahar El-Sallab
BRD | Director/Board Member | - | 2020-12-31 |
Company details: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +5.19% | +10.08% | -56.97% | -42.97% | 85.71M | ||
| +1.44% | +1.63% | +48.17% | +139.63% | 1,258B | ||
| -0.47% | +5.49% | +49.03% | +90.68% | 679B | ||
| +0.20% | +2.76% | +34.37% | +112.06% | 518B | ||
| +0.17% | +2.76% | +44.07% | +69.71% | 390B | ||
| -0.48% | +2.34% | +70.66% | +46.02% | 367B | ||
| +0.76% | +2.27% | +31.59% | +60.36% | 307B | ||
| -1.29% | +0.90% | +5.77% | +37.60% | 293B | ||
| 0.00% | +0.86% | +43.74% | +74.04% | 252B | ||
| +0.92% | +2.03% | +44.62% | +125.07% | 210B | ||
| Average | +0.49% | +1.70% | +31.51% | +71.22% | 427B | |
| Weighted average by Cap. | -0.09% | +1.18% | +43.66% | +96.83% |
Sector
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.420EGP
Average target price
1.570EGP
Spread / Average Target
+10.56%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- MCRO Stock
- Company Macro Group Pharmaceuticals (Macro Capital) S.A.E
Select your edition
All financial news and data tailored to specific country editions
















